Nanobiotix S.A. (NBTX) vs Phibro Animal Health (PAHC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Nanobiotix S.A. (NBTX) has outperformed Phibro Animal Health (PAHC) over the past year, gaining 26.6% versus a loss of 20.0%. Over five years, NBTX leads with a +214.0% price change compared with +59.4% for PAHC. Phibro Animal Health is the larger company by market cap ($1.35 billion vs $1.35 billion), about 1.0 times the size.
Phibro Animal Health pays a dividend yielding 1.44%, while Nanobiotix S.A. does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NBTX | PAHC |
|---|---|---|
| Share price | $26.50 | $33.29 |
| Market cap | $1.35B | $1.35B |
| 1-day change | -2.98% | -2.32% |
| YTD return | +14.62% | -10.89% |
| 1-year return | +26.61% | -20.03% |
| 5-year return | +213.98% | +59.43% |
| P/E ratio (TTM) | — | 13.26 |
| Forward P/E | — | 8.58 |
| EPS (TTM) | $-1.27 | $2.51 |
| Dividend yield | 0.00% | 1.44% |
| Annual dividend | $0.00 | $0.48 |
| Revenue (latest FY) | — | $1.52B |
| Revenue growth (YoY) | — | +17.12% |
| Net income (latest FY) | — | $99.72M |
| Gross margin | — | 33.76% |
| Operating margin | — | 12.81% |
| Net margin | — | 6.57% |
| 52-week high | $57.14 | $60.08 |
| 52-week low | $19.14 | $28.25 |
| Distance from 52-week high | -53.62% | -44.59% |
| Analyst consensus | none | hold |
| Avg. price target upside | +101.06% | +41.18% |
| Average volume | 148.94K | 228.99K |
| Shares outstanding | 50.95M | 21.11M |
| Employees | 98 | 2,605 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NBTX has outperformed PAHC by 46.6 percentage points over the past year.
- Phibro Animal Health offers a meaningfully higher dividend yield (1.44% vs 0.00%).
About Nanobiotix S.A.
NBTX stock →Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs.
Health Care · Biotechnology: Pharmaceutical Preparations · 98 employees
About Phibro Animal Health
PAHC stock →Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,605 employees
NBTX vs PAHC FAQ
Which is bigger, Nanobiotix S.A. or Phibro Animal Health?
Phibro Animal Health (PAHC) is larger, with a market capitalization of $1.35B compared with $1.35B for Nanobiotix S.A. (NBTX).
Which stock has performed better over the past year, NBTX or PAHC?
NBTX returned +26.61% over the past 12 months, compared with -20.03% for PAHC (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Nanobiotix S.A. or Phibro Animal Health?
Phibro Animal Health pays a dividend yielding 1.44%, while Nanobiotix S.A. does not currently pay a regular dividend.
Are Nanobiotix S.A. and Phibro Animal Health in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.